Uveal Melanoma – Standardised Procedure in Diagnosis, Therapy and Surveillance

Abstract

Background Uveal melanoma is a rare intraocular tumour, for which there is currently no national evidence-based guideline in Germany. The aim of this project was to provide a common standard operating procedure (SOP) for the diagnosis, treatment and follow-up care of uveal melanoma, within the network of German leading oncology centres funded by German Cancer Aid. The SOP was created as part of a moderated consensus process.

Results and Conclusion In a multistage process, a common SOP was developed for the diagnosis, therapy and follow-up of uveal melanoma, as based on current knowledge of the subject.

Key words

uveal melanoma - choroidal melanoma - iris melanoma - brachytherapy - proton beam radiotherapy - SOP

Publikationsverlauf

Eingereicht: 18. März 2021

Angenommen: 21. Juni 2021

Artikel online veröffentlicht:
10. August 2021

• References/Literatur

• 1 Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology 2003; 110: 956-961
• 2 Egan KM, Seddon JM, Glynn RJ. et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32: 239-251
• 3 Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology 2012; 119: 1582-1589
• 4 Smith JH, Padnick-Silver L, Newlin A. et al. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi. Ophthalmology 2007; 114: 774-779
• 5 Cheung M, Talarchek J, Schindeler K. et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 2013; 206: 206-210
• 6 AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancerʼs 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol 2015; 133: 376-383
• 7 Kujala E, Damato B, Coupland SE. et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol 2013; 31: 2825-2831
• 8 Coupland SE, Lake SL, Zeschnigk M. et al. Molecular pathology of uveal melanoma. Eye (Lond) 2013; 27: 230-242
• 9 van de Nes JA, Nelles J, Kreis S. et al. Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma. Am J Surg Pathol 2016; 40: 796-805
• 10 Vergara IA, Wilmott JS, Long GV. et al. Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. Exp Dermatol 2021;
• 11 Decatur CL, Ong E, Garg N. et al. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes. JAMA Ophthalmol 2016; 134: 728-733
• 12 Onken MD, Worley LA, Long MD. et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49: 5230-5234
• 13 Van Raamsdonk CD, Griewank KG, Crosby MB. et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-2199
• 14 Van Raamsdonk CD, Bezrookove V, Green G. et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602
• 15 Prescher G, Bornfeld N, Horsthemke B. et al. Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet 1992; 339: 691-692
• 16 Harbour JW, Onken MD, Roberson ED. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-1413
• 17 Martin M, Masshofer L, Temming P. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013; 45: 933-936
• 18 Yavuzyigitoglu S, Koopmans AE, Verdijk RM. et al. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. Ophthalmology 2016; 123: 1118-1128
• 19 Onken MD, Worley LA, Char DH. et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119: 1596-1603
• 20 Prescher G, Bornfeld N, Hirche H. et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-1225
• 21 Rodrigues M, Ait Rais K, Salviat F. et al. Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival. JAMA Ophthalmol 2020; 138: 182-188
• 22 Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 2010; 16: 6083-6092
• 23 Aughton K, Kalirai H, Coupland SE. MicroRNAs and Uveal Melanoma: Understanding the Diverse Role of These Small Molecular Regulators. Int J Mol Sci 2020; 21: 5648
• 24 Le Guin CHD, Metz KA, Lehmann N. et al. Chromosome 3 is a valid marker for prognostic testing of biopsy material from uveal melanoma later treated by brachytherapy. Biomarkers 2019; 24: 134-140
• 25 Moy CS, Albert DM, Diener-West M. et al. Cause-specific mortality coding. methods in the collaborative ocular melanoma study coms report no. 14. Control Clin Trials 2001; 22: 248-262
• 26 Leyvraz S, Piperno-Neumann S, Suciu S. et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC18021): a multicentric randomized trial. Ann Oncol 2014; 25: 742-746
• 27 Garg G, Finger PT, Kivelä TT. et al. Patients presenting with metastases: stage IV uveal melanoma, an international study. Br J Ophthalmol 2021;
• 28 Rantala ES, Hernberg MM, Lundin M. et al. Metastatic uveal melanoma managed with best supportive care. Acta Oncol 2021; 60: 135-139
• 29 Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 2019; 29: 561-568
• 30 Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C. et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res 2006; 38: 255-260
• 31 Gragoudas ES, Lane AM, Regan S. et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000; 118: 773-778
• 32 Char DH, Quivey JM, Castro JR. et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993; 100: 1547-1554
• 33 Singh AD, Kivela T. The collaborative ocular melanoma study. Ophthalmol Clin North Am 2005; 18: 129-142 ix
• 34 Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124: 1684-1693
• 35 Rao PK, Barker C, Coit DG. et al. NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. J Natl Compr Canc Netw 2020; 18: 120-131
• 36 Chau C, van Doorn R, van Poppelen NM. et al. Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines. Cancers (Basel) 2019; 11: 1114
• 37 Mathis T, Cassoux N, Tardy M. et al. [Management of uveal melanomas, guidelines for oncologists]. Bull Cancer 2018; 105: 967-980
• 38 Barker CA, Salama AK. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. J Natl Compr Canc Netw 2018; 16: 646-650
• 39 Nathan P, Cohen V, Coupland S. et al. Uveal Melanoma UK National Guidelines. Eur J Cancer 2015; 51: 2404-2412
• 40 American Brachytherapy Society – Ophthalmic Oncology Task Force, ABS – OOTF Committee. Electronic address pec, Committee AO. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13: 1-14
• 41 Seth R, Messersmith H, Kaur V. et al. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol 2020; 38: 3947-3970
• 42 Weis E, Salopek TG, McKinnon JG. et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol 2016; 23: e57-e64
• 43 Glossmann JP, Skoetz N, Starbatty B. et al. [Conjunctival melanoma: Standard operating procedures in diagnosis, treatment and follow-up care]. Ophthalmologe 2018; 115: 489-498
• 44 Seider MI, Berry DE, Schefler AC. et al. Multi-center analysis of intraocular biopsy technique and outcomes for uveal melanoma: Ocular Oncology Study Consortium report 4. Graefes Arch Clin Exp Ophthalmol 2020; 258: 427-435
• 45 Bagger MM. Intraocular biopsy of uveal melanoma Risk assessment and identification of genetic prognostic markers. Acta Ophthalmol 2018; 96 (Suppl. 112) S1-S28
• 46 Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol 2014; 1102: 427-440
• 47 Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology 2014; 121: 1281-1288
• 48 Grisanti S, Ranjbar M, Tura A. et al. [Uveal melanoma: Early detection as the key to successful personalized medicine]. Ophthalmologe 2020; 117: 508-520
• 49 Tarmann L, Wackernagel W, Avian A. et al. Ruthenium-106 plaque brachytherapy for uveal melanoma. Br J Ophthalmol 2015; 99: 1644-1649
• 50 Rouberol F, Roy P, Kodjikian L. et al. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 yearsʼ experience with beta-rays). Am J Ophthalmol 2004; 137: 893-900
• 51 Seregard S, aft Trampe E, Lax I. et al. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience. Acta Ophthalmol Scand 1997; 75: 11-16
• 52 Summanen P, Immonen I, Kivela T. et al. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol 1996; 80: 732-739
• 53 Gragoudas ES. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci 2006; 47: 4666-4673
• 54 Echegaray JJ, Bechrakis NE, Singh N. et al. Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose. Ocul Oncol Pathol 2017; 3: 193-198
• 55 Kosydar S, Robertson JC, Woodfin M. et al. Systematic Review and Meta-Analysis on the Use of Photon-based Stereotactic Radiosurgery Versus Fractionated Stereotactic Radiotherapy for the Treatment of Uveal Melanoma. Am J Clin Oncol 2021; 44: 32-42
• 56 Parker T, Rigney G, Kallos J. et al. Gamma knife radiosurgery for uveal melanomas and metastases: a systematic review and meta-analysis. Lancet Oncol 2020; 21: 1526-1536
• 57 Biewald E, Lautner H, Gok M. et al. Endoresection of large uveal melanomas: clinical results in a consecutive series of 200 cases. Br J Ophthalmol 2017; 101: 204-208
• 58 Suesskind D, Scheiderbauer J, Buchgeister M. et al. Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection. JAMA Ophthalmol 2013; 131: 630-637
• 59 Liegl R, Schmelter V, Fuerweger C. et al. Robotic CyberKnife Radiosurgery for Ciliary Body Melanoma. Ophthalmol Retina 2020; 4: 954-956
• 60 Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond) 2013; 27: 163-171
• 61 Blatsios G, Haas G, Zehetner C. et al. [Surgical Methods in the Treatment of Uveal Melanoma]. Klin Monbl Augenheilkd 2017; 234: 874-885
• 62 Seibel I, Riechardt AI, Heufelder J. et al. Adjuvant Ab Interno Tumor Treatment After Proton Beam Irradiation. Am J Ophthalmol 2017; 178: 94-100
• 63 Willerding GD, Cordini D, Moser L. et al. Neoadjuvant proton beam irradiation followed by transscleral resection of uveal melanoma in 106 cases. Br J Ophthalmol 2016; 100: 463-467
• 64 Damato B, Kacperek A, Errington D. et al. Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol 2013; 27: 151-157
• 65 Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C. et al. Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol 2012; 49: 41-57
• 66 Gunduz K, Bechrakis NE. Exoresection and endoresection for uveal melanoma. Middle East Afr J Ophthalmol 2010; 17: 210-216
• 67 Bechrakis NE, Petousis V, Willerding G. et al. Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol 2010; 94: 460-466
• 68 Bechrakis NE, Petousis V, Krause L. et al. [Surgical treatment modalities in uveal melanomas]. Klin Monbl Augenheilkd 2009; 226: 921-926
• 69 Bechrakis NE, Hocht S, Martus P. et al. [Endoresection following proton beam irradiation of large uveal melanomas]. Ophthalmologe 2004; 101: 370-376
• 70 Shields CL, Dalvin LA, Chang M. et al. Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals. JAMA Ophthalmol 2020; 138: 136-146
• 71 Oxenreiter MM, Lane AM, Aronow MB. et al. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field). Br J Ophthalmol 2020;
• 72 Leblanc A, Lumbroso-Le Rouic L, Desjardins L. et al. Diffuse Iris Melanoma: Conservative Treatment with Proton Beam Therapy after Limbal Stem Cell Preservation or Enucleation?. Ocul Oncol Pathol 2019; 5: 396-401
• 73 Riechardt AI, Klein JP, Cordini D. et al. Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects. Graefes Arch Clin Exp Ophthalmol 2018; 256: 1325-1332
• 74 Naumann GO, Rummelt V. Block excision of tumors of the anterior uvea. Report on 68 consecutive patients. Ophthalmology 1996; 103: 2017-2027 discussion 2027–2028
• 75 Rowcroft A, Loveday BPT, Thomson BNJ. et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford) 2020; 22: 497-505
• 76 Seregard S, Landau I. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma. Acta Ophthalmol Scand 2001; 79: 19-22
• 77 Tagliaferri L, Pagliara MM, Fionda B. et al. Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review. J Contemp Brachytherapy 2019; 11: 54-60
• 78 Riechardt AI, Cordini D, Dobner B. et al. Salvage proton beam therapy in local recurrent uveal melanoma. Am J Ophthalmol 2014; 158: 948-956
• 79 Cohen Y, Goldenberg-Cohen N, Parrella P. et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 2876-2878
• 80 Mariani P, Piperno-Neumann S, Servois V. et al. Surgical management of liver metastases from uveal melanoma: 16 yearsʼ experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-1197
• 81 Ponti A, Denys A, Digklia A. et al. First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. J Nucl Med 2020; 61: 350-356
• 82 Sussman TA, Funchain P, Singh A. Clinical Trials in Metastatic Uveal Melanoma: Current Status. Ocul Oncol Pathol 2020; 6: 381-387
• 83 Khoja L, Atenafu EG, Suciu S. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 2019; 30: 1370-1380
• 84 Pelster MS, Gruschkus SK, Bassett R. et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol 2021; 39: 599-607
• 85 Damato BE, Dukes J, Goodall H. et al. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers (Basel) 2019; 11: 971